公开(公告)号：US20240342287A1

公开(公告)日：2024-10-17

申请号：US18751743

申请日：2024-06-24

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61K41/00 ,  A61K31/37 ,  A61K45/06 ,  A61N5/06 ,  A61N5/10

CPC分类号： A61K41/0066 ,  A61K31/37 ,  A61N5/062 ,  A61N5/10 ,  A61K45/06 ,  A61N2005/0661 ,  A61N2005/1098

摘要： A kit for use in performing a cancer treatment, having a vial containing a phosphor-containing drug activator, wherein the phosphor-containing drug activator is present in the vial at a dosage level that is correlated with a size of tumor to be treated, and a container containing the vial;



wherein the phosphor-containing drug activator contains an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; where the two or more phosphors include Zn2SiO4:Mn2+ and (3Ca3(PO4)2Ca(F, Cl)2:Sb3+, Mn2+) at a ratio (Zn2SiO4:Mn2+):(3Ca3(PO4)2Ca(F, Cl)2:Sb3+, Mn2+)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating and a diamond-like carbon coating.

公开(公告)号：US20240042233A1

公开(公告)日：2024-02-08

申请号：US18360187

申请日：2023-07-27

申请人： Immunolight, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Wayne F. BEYER, JR. ,  Mark DEWHIRST ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61N5/06 ,  A61K41/17 ,  A61K39/00 ,  A61K41/00 ,  A61K49/04 ,  A61N5/02 ,  A61N5/10

CPC分类号： A61N5/062 ,  A61K41/17 ,  A61K39/0011 ,  A61K41/0066 ,  A61K49/0423 ,  A61N5/022 ,  A61N5/10 ,  A61N5/1081 ,  A61K2039/585 ,  A61N2005/0627 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1089 ,  A61N2005/1098

摘要： A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photoactivatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

公开(公告)号：US20170050046A1

公开(公告)日：2017-02-23

申请号：US15307766

申请日：2015-04-22

申请人： IMMUNOLIGHT, LLC. ,  DUKE UNIVERSITY ,  NORTH CAROLINA STATE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Mark W. DEWHIRST ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61N5/06 ,  A61B6/00 ,  A61N5/10 ,  A61K9/00 ,  A61K49/04 ,  A61K41/00 ,  A61K39/00 ,  A61B6/03 ,  A61N5/02

CPC分类号： A61N5/062 ,  A61K39/0011 ,  A61K41/0019 ,  A61K41/0066 ,  A61K49/0423 ,  A61K2039/585 ,  A61N5/022 ,  A61N5/10 ,  A61N5/1081 ,  A61N2005/0627 ,  A61N2005/0659 ,  A61N2005/0661 ,  A61N2005/0662 ,  A61N2005/1089 ,  A61N2005/1098

摘要： A system and method for imaging or treating a disease in a human or animal body. The system provides to the human or animal body a pharmaceutical carrier including one or more phosphors which are capable of emitting ultraviolet or visible light into the body and which provide x-ray contrast. The system includes one or more devices which infuse a diseased site with a photo-activatable drug and the pharmaceutical carrier, an initiation energy source comprising an x-ray or high energy source which irradiates the diseased site with at least one of x-rays, gamma rays, or electrons to thereby initiate emission of said ultraviolet or visible light into the body, and a processor programmed to at least one of 1) produce images of the diseased site or 2) control a dose of said x-rays, gamma rays, or electrons to the diseased site for production of said ultraviolet or visible light at the diseased site to activate the photoactivatable drug.

摘要翻译： 用于在人或动物体内成像或治疗疾病的系统和方法。 该系统向人体或动物体提供包含能够将紫外线或可见光发射到体内并提供x射线对比度的一种或多种磷光体的药物载体。 该系统包括一个或多个装置，其将病变部位注入可光活化药物和药物载体，引发能量源包括用X射线或高能量源照射患病部位的x射线， 伽马射线或电子，从而开始将所述紫外线或可见光发射到体内;以及处理器，被编程为以下中的至少一个：1）产生患病部位的图像，或2）控制所述X射线，γ射线的剂量 或电子到病变部位，以在病变部位产生所述紫外线或可见光，以活化可光活化药物。

公开(公告)号：US20220080045A1

公开(公告)日：2022-03-17

申请号：US17538770

申请日：2021-11-30

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Wayne F. BEYER ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61K41/00 ,  A61K31/37 ,  A61N5/06 ,  A61N5/10

摘要： A method for treating a disease in a subject in need thereof is provided involving infusing 8-methoxypsoralen (8-MOP) and a phosphor-containing drug activator into a diseased site in the subject; and delivering a dose of x-rays to the subject for production of the ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose including a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor, wherein the phosphor-containing drug activator includes an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; the two or more phosphors including Zn2SiO4:Mn2+ and (3Ca3(PO4)2Ca(F, Cl)2: Sb3+, Mn2+) at a ratio (Zn2SiO4:Mn2+):(3Ca3(PO4)2Ca(F, Cl)2: Sb3+, Mn2+)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating or a diamond-like carbon coating.

公开(公告)号：US20200282056A1

公开(公告)日：2020-09-10

申请号：US16074707

申请日：2017-02-02

申请人： IMMUNOLIGHT, LLC ,  DUKE UNIVERSITY

发明人： Harold WALDER ,  Frederic A. BOURKE, JR. ,  Zakaryae FATHI ,  Wayne BEYER ,  Mark OLDHAM ,  Justus ADAMSON ,  Michael NOLAN

IPC分类号： A61K41/00 ,  A61K31/37 ,  A61N5/06 ,  A61N5/10

摘要： A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier. A system for treating a disease in a subject in need thereof includes a) the above-noted suspension, b) a photoactivatable drug containing 8-methoxypsoralen (8-MOP or UVADEX) untethered from the two or more phosphors, c) one or more devices which infuse the photoactivatable drug and the suspension including the pharmaceutically acceptable carrier into a diseased site in the subject, and d) an x-ray source which is controlled to deliver a dose of x-rays to the subject for production of the ultraviolet light.